Abstract |
Ehrlich carcinoma and P388 leukemia cells were rendered resistant to 4-carbamoylimidazolium 5-olate (SM-108), and assessments were made of biochemical and pharmacological determinants for the sensitivity to SM-108 using both sensitive and resistant sublines. We observed that the treatment of cells with SM-108 in vitro caused a remarkable decrease in the intracellular guanosine 5'-triphosphate pool level in sensitive but not in resistant sublines. There was no difference in the ability to take up SM-108 between sensitive and resistant sublines, but the cellular conversion of SM-108 to its nucleotide, which is the putative active anabolite of SM-108, proceeded only in sensitive sublines. Enzymological studies revealed that the activity of adenine phosphoribosyltransferase (EC 2.4.2.7), which is believed to conjugate SM-108 with 5-phospho-alpha-D-ribose 1-diphosphate, was very low in the resistant sublines. These results strongly support our previous hypothesis that SM-108 is activated by adenine phosphoribosyltransferase to SM-108-nucleotide which then inhibits hypoxanthine-5'-monophosphate dehydrogenase (EC 1.2.1.14), a key enzyme for the de novo synthesis of guanosine 5'-monophosphate.
|
Authors | M Fukui, M Inaba, S Tsukagoshi, Y Sakurai |
Journal | Cancer research
(Cancer Res)
Vol. 46
Issue 1
Pg. 43-6
(Jan 1986)
ISSN: 0008-5472 [Print] United States |
PMID | 2866032
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Imidazoles
- 5-carbamoyl-1H-imidazol-4-yl-piperonylate
- Guanosine Triphosphate
- IMP Dehydrogenase
- Adenine Phosphoribosyltransferase
- 4-carbamoylimidazolium 5-olate
|
Topics |
- Adenine Phosphoribosyltransferase
(metabolism)
- Animals
- Carcinoma, Ehrlich Tumor
(metabolism)
- Cell Line
- Drug Resistance
- Guanosine Triphosphate
(metabolism)
- IMP Dehydrogenase
(antagonists & inhibitors)
- Imidazoles
(pharmacology)
- Leukemia P388
(metabolism)
- Mice
- Neoplasms, Experimental
(metabolism)
|